STAAR Surgical Company reaffirmed sales guidance for the year 2022. For the year, the company reaffirming previously provided outlook for fiscal 2022 net sales of approximately $295 million, which takes into account a significant currency headwind and a continuation of the current level of COVID-19 related challenges in China and elsewhere, offset by stronger than expected demand for EVO lenses, which has continued through the beginning of the third quarter.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.51 USD | -0.68% | -2.61% | +36.21% |
May. 08 | Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating | MT |
May. 08 | Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.21% | 2.09B | |
-6.46% | 179B | |
+3.39% | 113B | |
-3.68% | 67.88B | |
+5.44% | 52.03B | |
+5.70% | 43.3B | |
+4.45% | 41.79B | |
+25.42% | 32.49B | |
+14.13% | 25.65B | |
-4.29% | 24.55B |
- Stock Market
- Equities
- STAA Stock
- News STAAR Surgical Company
- STAAR Surgical Company Re-Affirms Sales Guidance for the Year 2022